Drug Profile
GP 3367
Latest Information Update: 16 Aug 2002
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Class Small molecules
- Mechanism of Action Adenosine deaminase inhibitors; AMP deaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 29 Oct 1998 New profile
- 29 Oct 1998 Preclinical development for Ischaemic heart disorders in USA (Unknown route)